Neurogenin 2 CRISPR/Cas9 KO Plasmid (m): sc-419233
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Neurogenin 2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Neurogenin 2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Neurogenin 2 Antibody (2A8): sc-293430
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Neurogenin 2 CRISPR/Cas9 KO Plasmid (m) | sc-419233 | 20 µg | $397.00 |
Overview
Neurog2 encodes the basic helix–loop–helix transcription factor Neurogenin 2, a master regulator of neuronal lineage commitment during mouse embryonic development. Neurogenin 2 drives proneural gene expression programs and coordinates cell-cycle exit, neuronal differentiation, and migration through transcriptional networks that interface with Notch signaling and downstream bHLH factors. It is critical for specification of multiple neuronal subtypes in the developing central and peripheral nervous systems and for timing of neurogenesis. Dysregulated NEUROG2-dependent programs have been implicated in neurodevelopmental phenotypes and altered neuronal differentiation states relevant to modeling developmental brain disorders.
Neurogenin 2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Neurog2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Neurog2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Neurog2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Neurogenin 2 protein expression.
This CRISPR knockout system enables efficient generation of Neurog2-deficient cell models for investigation of Neurogenin 2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Neurog2 exon(s) critical for Neurogenin 2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Neurog2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Neurogenin 2 CRISPR/Cas9 KO Plasmid (m) and Neurogenin 2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Neurog2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Neurogenin 2 HDR Plasmid (m) and Neurogenin 2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Neurog2 homology arms to support homology-directed repair at defined Neurog2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.